Andere Sprachen Peak Bio, Inc.

Aktien

A3DZGQ

US70470P1084

PKBO

Verzögert OTC Markets Andere Börsenplätze 19:11:26 30.05.2024			% 5 Tage	% 1. Jan.
0.0086 ^USD	-.--%		-.--%	-95.41%

2023	Peak Bio, Inc. ernennt Michael Friedman zum Vorstandsmitglied und Mitglied des Prüfungsausschusses und des Vergütungsausschusses	CI
2023	Peak Bio, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders	06.06.
Peak Bio, Inc. announced that it has received $1.3245 million in funding	28.05.
Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc..	05.03.
Peak Bio, Inc. announced that it has received $2.238 million in funding	16.02.
Peak Bio, Inc. Receives Loan in the Principal Amount of $750,000	29.01.
Peak Bio, Inc. announced that it has received $0.075 million in funding	23.01.
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing	04.01.
Peak Bio, Inc. announced a financing transaction	18.12.
Peak Bio : Private Placement - Form 8-K	02.11.
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing	19.09.23
Peak Bio, Inc. Announces Up-listing to OTCQB Market	31.08.23
Peak Bio, Inc. Announces Up-listing to OTCQB Market	31.08.23
Peak Bio, Inc. Appoints Michael Friedman to Board of Directors and Member of Audit Committee and Compensation Committee	31.08.23
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors	31.08.23
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors	31.08.23
Peak Bio, Inc. Announces its Application to Uplist to the OTCQB Venture Market	29.08.23
Peak Bio, Inc. Announces its Application to Uplist to the OTCQB Venture Market	29.08.23
Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital	24.08.23
Peak Bio, Inc. announced that it expects to receive $100 million in funding from White Lion Capital Llc	24.08.23
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting	23.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Peak Bio, Inc.

Aktien

A3DZGQ

US70470P1084

PKBO

Andere Sprachen

Filter